Quarterly report pursuant to Section 13 or 15(d)

Common Stock Warrants

v3.5.0.2
Common Stock Warrants
9 Months Ended
Sep. 30, 2016
Warrants And Rights Note Disclosure [Abstract]  
Common Stock Warrants

9. Common Stock Warrants

As of September 30, 2016 and December 31, 2015, the following common stock warrants were outstanding:

Issuance Date

 

Expiration Date

 

Balance Sheet Classification

 

Exercise Price

per Share

 

 

September 30,

2016

 

 

December 31,

2015

 

December 2011

 

December 2016

 

Stockholders' deficit

 

$

22.80

 

 

 

13,158

 

 

 

13,158

 

March 2012

 

March 2017

 

Contingent warrant liabilities

 

$

35.20

 

 

 

479,277

 

 

 

479,277

 

September 2012

 

September 2017

 

Stockholders' deficit

 

$

70.80

 

 

 

1,967

 

 

 

1,967

 

December 2014

 

December 2016

 

Contingent warrant liabilities

 

$

158.01

 

 

 

404,833

 

 

 

404,833

 

February 2015

 

February 2020

 

Stockholders' deficit

 

$

66.20

 

 

 

9,063

 

 

 

9,063

 

February 2016

 

February 2021

 

Stockholders' deficit

 

$

15.40

 

 

 

8,249

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

916,547

 

 

 

908,298

 

In February 2016, in conjunction with services provided by a third-party consultant, the Company issued a warrant to purchase up to an aggregate of 8,249 unregistered shares of XOMA’s common stock at an exercise price equal to $15.40 per share. These warrants were exercisable immediately and have a five-year term expiring in February 2021. The estimated fair value of the warrants of $0.1 million was calculated using the Black-Scholes Model and was classified in stockholders’ deficit on the condensed consolidated balance sheet.

The Company revalued the December 2014 warrants at September 30, 2016 using the Black-Scholes Model and recorded zero and a $3.0 million decrease in the estimated fair value as a gain in the revaluation of contingent warrant liabilities line of the Company’s condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2016, respectively. The Company revalued the March 2012 warrants at September 30, 2016 using the Black-Scholes Model and recorded a $0.3 million and $7.5 million decrease in the estimated fair value as a gain in the revaluation of contingent warrant liabilities line of the Company’s condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2016, respectively. The decrease in these liabilities is primarily due to the decrease in the market price of XOMA’s common stock at September 30, 2016 as compared to December 31, 2015. 

As of September 30, 2016 and December 31, 2015, the December 2014 warrants had an estimated fair value of zero and $3.0 million, respectively. As of September 30, 2016 and December 31, 2015, the March 2012 warrants had an estimated fair value of $9,000 and $7.5 million, respectively.